Press Release: Alios Biopharma : Medivir announces that development of the HCV nucleotide polymerase inhibitor AL-704 was terminated by Janssen

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIRB) today announces that the development of AL-704 (also known as JNJ-54257099) has been terminated following completion of phase I clinical studies conducted by Alios Biopharma Inc., one of the Janssen Pharmaceutical Companies. These studies demonstrated that AL-704 was safe, well tolerated and had acceptable pharmacokinetic properties. However its clinical antiviral activity in persons infected with HCV genotype 1 was insu